The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency.
Open accessAbstract
Atherosclerosis develops rapidly in patients with diabetes or renal insufficiency. Plasma lipoprotein profiles are frequently abnormal in these conditions and reflect an elevation in the level of the apoprotein B (ApoB)-containing components very low density lipoprotein (VLDL) and low density lipoprotein (LDL). High levels of circulating advanced glycation end products (AGEs) also occur in diabetes and end-stage renal disease (ESRD). These products arise from glucose-derived Amadori products and include AGE-modified peptides (AGE-peptides) which result from the catabolism of AGE-modified tissue proteins. AGE-peptides have been shown to crosslink protein amino groups and to accumulate in plasma as a consequence of renal insufficiency. To address potential mechanisms for the dyslipidemia of diabetes and ESRD, we investigated the possibility that circulating AGEs react directly with plasma lipoproteins to prevent their recognition by tissue LDL receptors. AGE-specific ELISA showed a significantly increased level of AGE-modified LDL in the plasma of diabetic or ESRD patients compared with normal controls. AGE-LDL formed readily in vitro when native LDL was incubated with either synthetic AGE-peptides or AGE-peptides isolated directly from patient plasma. LDL which had been modified by AGE-peptides in vitro to the same level of modification as that present in the plasma of diabetics with renal insufficiency exhibited markedly impaired clearance kinetics when injected into transgenic mice expressing the human LDL receptor. These data indicate that AGE modification significantly impairs LDL-receptor-mediated clearance mechanisms and may contribute to elevated LDL levels in patients with diabetes or renal insufficiency. This hypothesis was further supported by the observation that the administration of the advanced glycation inhibitor aminoguanidine to diabetic patients decreased circulating LDL levels by 28%.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Havel, R. J., Eder, H. A., & Bragdon, J. H. (1955) · Journal of Clinical Investigation · doi:10.1172/jci103182 · Cited by 8,760
Epstein, F. H., Steinberg, D., Parthasarathy, S., Carew, T. E., Khoo, J. C., & Witztum, J. L. (1989) · New England Journal of Medicine · doi:10.1056/nejm198904063201407 · Cited by 6,427
The Pathogenesis of Atherosclerosis — An Update
Ross, R. (1986) · New England Journal of Medicine · doi:10.1056/nejm198602203140806 · Cited by 4,877
Diabetes and Cardiovascular Disease: The Framingham Study
Kannel, W. B. (1979) · JAMA · doi:10.1001/jama.1979.03290450033020 · Cited by 2,936
Advanced Glycosylation End Products in Tissue and the Biochemical Basis of Diabetic Complications
Flier, J. S., Underhill, L. H., Brownlee, M., Cerami, A., & Vlassara, H. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805193182007 · Cited by 2,511
Self-citationThe Low-Density Lipoprotein Pathway and its Relation to Atherosclerosis
Goldstein, L. J., & Brown, S. M. (1977) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.46.070177.004341 · Cited by 1,906
Bucala, R., Tracey, K. J., & Cerami, A. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115014 · Cited by 1,165
Self-citationAminoguanidine Prevents Diabetes-Induced Arterial Wall Protein Cross-Linking
Brownlee, M., Vlassara, H., Kooney, A., Ulrich, P., & Cerami, A. (1986) · Science · doi:10.1126/science.3487117 · Cited by 1,146
Self-citationAdvanced Glycosylation End Products in Patients with Diabetic Nephropathy
Makita, Z., Radoff, S., Rayfield, E. J., Yang, Z., Skolnik, E., Delaney, V., Friedman, E. A., Cerami, A., & Vlassara, H. (1991) · New England Journal of Medicine · doi:10.1056/nejm199109193251202 · Cited by 918
Self-citationAccelerated age-related browning of human collagen in diabetes mellitus.
Monnier, V. M., Kohn, R. R., & Cerami, A. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.2.583 · Cited by 671
Self-citation
Cited by
Advanced Glycation End Products: Sparking the Development of Diabetic Vascular Injury
Goldin, A., Beckman, J. A., Schmidt, A. M., & Creager, M. A. (2006) · Circulation · doi:10.1161/circulationaha.106.621854 · Cited by 2,261
Advanced glycation endproducts—role in pathology of diabetic complications
Ahmed, N. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2004.09.004 · Cited by 1,455
BASTA, G. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.05.001 · Cited by 999
The Role of Advanced Glycation End Products in Progression and Complications of Diabetes
Goh, S.-Y., & Cooper, M. E. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1817 · Cited by 987
Koschinsky, T., He, C.-J., Mitsuhashi, T., Bucala, R., Liu, C., Buenting, C., Heitmann, K., & Vlassara, H. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.12.6474 · Cited by 792
Self-citationGlycemic Control and Heart Failure Among Adult Patients With Diabetes
Iribarren, C., Karter, A. J., Go, A. S., Ferrara, A., Liu, J. Y., Sidney, S., & Selby, J. V. (2001) · Circulation · doi:10.1161/01.cir.103.22.2668 · Cited by 710
Diabetes and advanced glycation endproducts
Vlassara, H., & Palace, M. R. (2002) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2002.00932.x · Cited by 697
Self-citationUse of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts
Thornalley, P. J. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2003.08.013 · Cited by 682
Chaudhuri, J., Bains, Y., Guha, S., Kahn, A., Hall, D., Bose, N., Gugliucci, A., & Kapahi, P. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.08.014 · Cited by 669
Role of reactive aldehyde in cardiovascular diseases
Uchida, K. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00226-4 · Cited by 606
Bierhaus, A. (1998) · Cardiovascular Research · doi:10.1016/s0008-6363(97)00233-2 · Cited by 555
Tobacco smoke is a source of toxic reactive glycation products
Cerami, C., Founds, H., Nicholl, I., Mitsuhashi, T., Giordano, D., Vanpatten, S., Lee, A., Al-Abed, Y., Vlassara, H., Bucala, R., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.25.13915 · Cited by 549
Self-citationReddy, S., Bichler, J., Wells-Knecht, K. J., Thorpe, S. R., & Baynes, J. W. (1995) · Biochemistry · doi:10.1021/bi00034a021 · Cited by 524
Glycoxidation and lipoxidation in atherogenesis
Baynes, J. W., & Thorpe, S. R. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00228-8 · Cited by 514
How hyperglycemia promotes atherosclerosis: molecular mechanisms
Aronson, D., & Rayfield, E. J. (2002) · Cardiovascular Diabetology · doi:10.1186/1475-2840-1-1 · Cited by 504
Papachristoforou, E., Lambadiari, V., Maratou, E., & Makrilakis, K. (2020) · Journal of Diabetes Research · doi:10.1155/2020/7489795 · Cited by 479
An agent cleaving glucose-derived protein crosslinks in vitro and in vivo
Vasan, S., Zhang, X., Zhang, X., Kapurniotu, A., Bernhagen, J., Teichberg, S., Basgen, J., Wagle, D., Shih, D., Terlecky, I., et al. (1996) · Nature · doi:10.1038/382275a0 · Cited by 466
Self-citationAdvanced glycation end products induce glomerular sclerosis and albuminuria in normal rats.
Vlassara, H., Striker, L. J., Teichberg, S., Fuh, H., Li, Y. M., & Steffes, M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.24.11704 · Cited by 462
Self-citationA synopsis on aging—Theories, mechanisms and future prospects
da Costa, J. P., Vitorino, R., Silva, G. M., Vogel, C., Duarte, A. C., & Rocha-Santos, T. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.06.005 · Cited by 456
Antioxidative and Anti-Glycation Activity of Garcinol from Garcinia indica Fruit Rind
Yamaguchi, F., Ariga, T., Yoshimura, Y., & Nakazawa, H. (2000) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf990845y · Cited by 448
Endothelial dysfunction and pathogenesis of diabetic angiopathy
Stehouwer, C. (1997) · Cardiovascular Research · doi:10.1016/s0008-6363(96)00272-6 · Cited by 441
Dietary Advanced Glycation End Products and Aging
Luevano-Contreras, C., & Chapman-Novakofski, K. (2010) · Nutrients · doi:10.3390/nu2121247 · Cited by 396
Meerwaldt, R., Hartog, J. W. L., Graaff, R., Huisman, R. J., Links, T. P., den Hollander, N. C., Thorpe, S. R., Baynes, J. W., Navis, G., Gans, R. O. B., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005020144 · Cited by 396
Advanced glycation end products and the kidney
Bohlender, J. M., Franke, S., Stein, G., & Wolf, G. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00398.2004 · Cited by 387
Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat
Degenhardt, T. P., Alderson, N. L., Arrington, D. D., Beattie, R. J., Basgen, J. M., Steffes, M. W., Thorpe, S. R., & Baynes, J. W. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00207.x · Cited by 378
Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice
Lalla, E., Lamster, I. B., Feit, M., Huang, L., Spessot, A., Qu, W., Kislinger, T., Lu, Y., Stern, D. M., & Schmidt, A. M. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8942 · Cited by 375
Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms
Stirban, A., Gawlowski, T., & Roden, M. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2013.11.006 · Cited by 361
Atherosclerosis and arteriosclerosis in chronic renal failure
London, G. M., & Drüeke, T. B. (1997) · Kidney International · doi:10.1038/ki.1997.233 · Cited by 354
Role of advanced glycation end products in cardiovascular disease
Hegab, Z. (2012) · World Journal of Cardiology · doi:10.4330/wjc.v4.i4.90 · Cited by 354
The role of oxidative stress and NF‐κB activation in late diabetic complications
Mohamed, A. K., Bierhaus, A., Schiekofer, S., Tritschler, H., Ziegler, R., & Nawroth, P. P. (1999) · BioFactors · doi:10.1002/biof.5520100211 · Cited by 339
Diabetes and Advanced Glycoxidation End Products
Huebschmann, A. G., Regensteiner, J. G., Vlassara, H., & Reusch, J. E. B. (2006) · Diabetes Care · doi:10.2337/dc05-2096 · Cited by 330
Self-citationCai, W., Ramdas, M., Zhu, L., Chen, X., Striker, G. E., & Vlassara, H. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205847109 · Cited by 325
Self-citationInsulin Resistance and Atherosclerosis
Nigro, J., Osman, N., Dart, A. M., & Little, P. J. (2006) · Endocrine Reviews · doi:10.1210/er.2005-0007 · Cited by 314
Yamagishi, S.-I., Inagaki, Y., Okamoto, T., Amano, S., Koga, K., Takeuchi, M., & Makita, Z. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202634200 · Cited by 310
Self-citationPrevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group I: Epidemiology
Howard, B. V., Rodriguez, B. L., Bennett, P. H., Harris, M. I., Hamman, R., Kuller, L. H., Pearson, T. A., & Wylie-Rosett, J. (2002) · Circulation · doi:10.1161/01.cir.0000013953.41667.09 · Cited by 308
The AGE‐receptor in the pathogenesis of diabetic complications
Vlassara, H. (2001) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.233 · Cited by 301
Self-citationThe Pathophysiology of Cardiovascular Disease and Diabetes: Beyond Blood Pressure and Lipids
Dokken, B. B. (2008) · Diabetes Spectrum · doi:10.2337/diaspect.21.3.160 · Cited by 299
Advanced Glycation End-Products (AGEs) and Heart Failure: Pathophysiology and Clinical Implications
Hartog, J. W. L., Voors, A. A., Bakker, S. J. L., Smit, A. J., & van Veldhuisen, D. J. (2007) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2007.09.009 · Cited by 299
Advanced glycation end products: A nephrologist's perspective
Raj, D. S. C., Choudhury, D., Welbourne, T. C., & Levi, M. (2000) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(00)70189-2 · Cited by 290
Role of the Maillard Reaction in Diabetes Mellitus and Diseases of Aging
Thorpe, S. R., & Baynes, J. W. (1996) · Drugs & Aging · doi:10.2165/00002512-199609020-00001 · Cited by 285
AGE restriction in diabetes mellitus: a paradigm shift
Vlassara, H., & Striker, G. E. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.74 · Cited by 277
Self-citationAngiogenesis induced by advanced glycation end products and its prevention by cerivastatin
Okamoto, T., Yamagishi, S., Inagaki, Y., Amano, S., Koga, K., Abe, R., Takeuchi, M., Ohno, S., Yoshimura, A., & Makita, Z. (2002) · The FASEB Journal · doi:10.1096/fj.02-0030fje · Cited by 258
Self-citationAthyros, V. G., Papageorgiou, A. A., Athyrou, V. V., Demitriadis, D. S., & Kontopoulos, A. G. (2002) · Diabetes Care · doi:10.2337/diacare.25.7.1198 · Cited by 257
The glyoxalase pathway: the first hundred years… and beyond
Sousa Silva, M., Gomes, R. A., Ferreira, A. E. N., Ponces Freire, A., & Cordeiro, C. (2013) · Biochemical Journal · doi:10.1042/bj20121743 · Cited by 256
Cai, W., He, J. C., Zhu, L., Peppa, M., Lu, C., Uribarri, J., & Vlassara, H. (2004) · Circulation · doi:10.1161/01.cir.0000135587.92455.0d · Cited by 177
Self-citationLipoxidation in cardiovascular diseases
Gianazza, E., Brioschi, M., Fernandez, A. M., & Banfi, C. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101119 · Cited by 152
Kilhovd, B. K., Juutilainen, A., Lehto, S., Rönnemaa, T., Torjesen, P. A., Birkeland, K. I., Berg, T. J., Hanssen, K. F., & Laakso, M. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000158380.44231.fe · Cited by 122
Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents?
Stern, M. P. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-1_part_2-199601011-00006 · Cited by 115
Kidney, heart and brain: three organs targeted by ageing and glycation
Frimat, M., Daroux, M., Litke, R., Nevière, R., Tessier, F. J., & Boulanger, E. (2017) · Clinical Science · doi:10.1042/cs20160823 · Cited by 88
Neelofar, K., & Ahmad, J. (2019) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2018.08.007 · Cited by 18
Metadata
- Authors
- Bucala, R., Makita, Z., Vega, G., Grundy, S., Koschinsky, T., Cerami, A., & Vlassara, H.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1994-09-27
- Volume
- 91
- Issue
- 20
- Pages
- 9441-9445
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2056258976
- Cited by
- 474
- References
- 34
- FWCI
- 14.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.